LABCORP HOLDINGS INC.
LHNYSE · SIC 8071
$283.36
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +16.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$23.5B
Enterprise Value
$28.8B
P/E
25.1
P/S
1.7
P/B
2.7
EV/EBITDA
13.6
PEG
—
FCF Yield
5.9%
Dividend Yield
1.0%
Revenue (TTM)
$14.1B
Net Income (TTM)
$942.0M
Free Cash Flow (TTM)
$1.4B
Gross Margin
28.8%
Operating Margin
10.2%
Net Margin
6.7%
ROE
10.8%
ROIC
8.1%
Debt / Equity
0.7
Net Cash
-$5.4B
Return 1Y
+15.8%
Company profile
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, and prostate-specific antigens. The company also provides specialty testing services, including gene-based and esoteric testing.
- CEO
- Adam H. Schechter
- Sector
- Services
- Industry
- Healthcare
- Employees
- 75,500
- Headquarters
- North Carolina
- Website
- labcorp.com
Management & directors
- Kyle Kathryn WEVP, Chief Legal Officer
- Vaughn Bryan TEVP and President, Diagnostics
- Schechter Adam HPresident & CEO
- Meltzer Jonathan CEVP, Operations
- Wilkinson Peter JSVP, Chief Accounting Officer
- Bailey Megan D.EVP, Pres, Central Labs & Intl
- Caveney Brian JEVP, Pres of ED, CMO & CSO
- Graham Anita ZEVP, CHRO
- Oyegunwa AkinboladeEVP, CIO & CTO
- Schroeder Mark SEVP, Pres Diagnostics & COO
- Summy Amy B.EVP, Chief Marketing Officer
- Van Der Vaart Sandra DEVP, Chief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-30
LH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.5B↑ +5.8%
Diluted EPS$3.35↑ +32.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $14.0B | $13.1B | $11.9B | $12.2B | $13.0B | $14.0B |
| Gross profit | $5.0B | $5.0B | $3.7B | $3.4B | $3.6B | $4.0B |
| Operating income | $2.4B | $3.0B | $1.4B | $725.6M | $1.1B | $1.4B |
| Net income | $1.6B | $2.4B | $1.3B | $418.0M | $746.0M | $877.0M |
| Diluted EPS | $15.88 | $24.39 | $13.97 | $4.77 | $8.84 | $10.46 |
| Operating cash flow | $2.1B | $3.1B | $2.0B | $1.3B | $1.6B | $1.6B |
| Free cash flow | $1.8B | $2.7B | $1.5B | $874.1M | $1.1B | $1.2B |
| Gross margin | 35.4% | 38.0% | 31.3% | 27.7% | 27.9% | 28.8% |
| Operating margin | 17.5% | 23.2% | 12.1% | 6.0% | 8.4% | 9.9% |
| Net margin | 11.1% | 18.1% | 10.8% | 3.4% | 5.7% | 6.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.3B | $3.3B | $3.3B | $3.5B | $3.6B | $3.5B | $3.5B |
| Gross profit | $926.4M | $904.4M | $896.3M | $948.0M | $1.0B | $1.0B | $993.2M | $1.0B |
| Operating income | $294.8M | $254.1M | $216.5M | $326.0M | $394.5M | $396.6M | $267.6M | $380.8M |
| Net income | $205.3M | $169.3M | $143.4M | $212.8M | $237.9M | $261.1M | $165.2M | $277.8M |
| Diluted EPS | $2.43 | $2.00 | $1.72 | $2.52 | $2.84 | $3.12 | $1.98 | $3.35 |
| Operating cash flow | $561.1M | $277.3M | $777.2M | $18.5M | $620.6M | $387.2M | $614.2M | $191.5M |
| Free cash flow | $432.9M | $161.5M | $665.1M | -$107.5M | $542.7M | $280.5M | $490.3M | $70.5M |
| Gross margin | 28.8% | 27.6% | 26.9% | 28.3% | 29.7% | 28.8% | 28.2% | 28.7% |
| Operating margin | 9.2% | 7.7% | 6.5% | 9.7% | 11.2% | 11.1% | 7.6% | 10.8% |
| Net margin | 6.4% | 5.2% | 4.3% | 6.4% | 6.7% | 7.3% | 4.7% | 7.9% |
Company news
Jul 15, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Vaughn Bryan T· EVP and President, Diagnostics | Sale | 234 | $286.19 | $66,968.46 | filing |
| 2026-07-02 | Kyle Kathryn W· EVP, Chief Legal Officer | Sale | 92 | $286.19 | $26,329.48 | filing |
| 2026-07-01 | Vaughn Bryan T· EVP and President, Diagnostics | Tax withholding | 93 | $283.88 | $26,400.84 | filing |
| 2026-07-01 | Kyle Kathryn W· EVP, Chief Legal Officer | Tax withholding | 73 | $283.88 | $20,723.24 | filing |
| 2026-07-01 | Vaughn Bryan T· EVP and President, Diagnostics | Option exercise | 327 | — | — | filing |
| 2026-07-01 | Kyle Kathryn W· EVP, Chief Legal Officer | Option exercise | 256 | — | — | filing |
| 2026-06-08 | Kyle Kathryn W· EVP, Chief Legal Officer | Sale | 762 | $263.89 | $201,084.18 | filing |
| 2026-05-11 | Schechter Adam H· President & CEO | Sale | 5,903 | $254.50 | $1.5M | filing |
| 2026-03-27 | Wilkinson Peter J· SVP, Chief Accounting Officer | Sale | 1,633 | $267.05 | $436,092.65 | filing |
| 2026-03-27 | Meltzer Jonathan C· EVP, Operations | Sale | 839 | $267.05 | $224,054.95 | filing |
| 2026-03-26 | Schechter Adam H· President & CEO | Tax withholding | 26,106 | $268.38 | $7.0M | filing |
| 2026-03-26 | Schroeder Mark S· EVP, Pres Diagnostics & COO | Tax withholding | 4,600 | $268.38 | $1.2M | filing |
| 2026-03-26 | Caveney Brian J· EVP, Pres of ED, CMO & CSO | Tax withholding | 4,042 | $268.38 | $1.1M | filing |
| 2026-03-26 | GRAHAM ANITA Z· EVP, CHRO | Tax withholding | 2,879 | $268.38 | $772,666.02 | filing |
| 2026-03-26 | van der Vaart Sandra D· EVP, Corporate Affairs | Tax withholding | 2,722 | $268.38 | $730,530.36 | filing |
| 2026-03-26 | Summy Amy B.· EVP, Chief Marketing Officer | Tax withholding | 1,836 | $268.38 | $492,745.68 | filing |
| 2026-03-26 | Schroeder Mark S· EVP, Pres Diagnostics & COO | Tax withholding | 1,468 | $268.38 | $393,981.84 | filing |
| 2026-03-26 | Caveney Brian J· EVP, Pres of ED, CMO & CSO | Tax withholding | 863 | $268.38 | $231,611.94 | filing |
| 2026-03-26 | Wilkinson Peter J· SVP, Chief Accounting Officer | Tax withholding | 755 | $268.38 | $202,626.90 | filing |
| 2026-03-26 | Meltzer Jonathan C· EVP, Operations | Tax withholding | 711 | $268.38 | $190,818.18 | filing |
| 2026-03-26 | Bailey Megan D.· EVP, Pres, Central Labs & Intl | Tax withholding | 481 | $268.38 | $129,090.78 | filing |
| 2026-03-26 | Kyle Kathryn W· EVP, Chief Legal Officer | Tax withholding | 451 | $268.38 | $121,039.38 | filing |
| 2026-03-26 | Vaughn Bryan T· EVP, Diagnostics | Tax withholding | 451 | $268.38 | $121,039.38 | filing |
| 2026-03-26 | Oyegunwa Akinbolade· EVP, CIO & CTO | Tax withholding | 382 | $268.38 | $102,521.16 | filing |
| 2026-03-26 | Vaughn Bryan T· EVP, Diagnostics | Award | 1,584 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.